Iovance Biotherapeutics, Inc. · NASDAQ:IOVA
Iovance Biotherapeutics — Investor Presentation (November 2026)
37 slides from Iovance Biotherapeutics's investor presentation, Nov 5, 2026
Slide 1: Corporate Overview November 2026
Corporate Overview November 2026 Exhibit 99.1 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Witho
Slide 3: Global Leader in Innovating, Developing and Delivering TIL Therapy for Patients with Cancer
Global Leader in Innovating, Developing and Delivering TIL Therapy for Patients with Cancer 3 Approved Products Commercial Launch Financials >100 Treatment Centers as of 11/05/26 2 >95% © 2026, Iovance Biotherapeutics, Inc. *The midpoint represents an increase of $55 million, or ~15%, over the previ
Slide 4: Strong Platform Supports Backbone IO Therapy for Solid Tumors
Strong Platform Supports Backbone IO Therapy for Solid Tumors Iovance Retains Global Portfolio and Technology Platform Rights *Advanced Non-squamous NSCLC wild type for EGFR, ALK, ROS1 **Advanced non-squamous NSCLC wild type for EGFR, ALK, ROS1, KRAS, HER2, current or prior smokers. ***UPS & DDLPS A
Slide 5: The Pioneer in One-Time Cell Therapy for Solid Tumors
The Pioneer in One-Time Cell Therapy for Solid Tumors 5 5 © 2026, Iovance Biotherapeutics, Inc. 1. Medina et al, ASCO 2025. Pooled Analysis (n=153), Heavily Pre-Treated Patient Population; 2. Karapetyan L et al. Transplantation & Cell Therapy 2026. Physician-assessed confirmed ORR by RECIST v1.1. Al
Slide 6: Significant U.S. Commercial Business Growth and Progress in Global Expansion
Significant U.S. Commercial Business Growth and Progress in Global Expansion
Slide 7: Significant Unmet Need in Frontline and Beyond
Significant Unmet Need in Frontline and Beyond1 Advanced Melanoma Market Opportunity 2L+ Advanced Melanoma Population2,3 U.S.: 8.5K Potential ex-US Markets: 24K+ Overall (1L+): 70K+ BRAF wild-type (prior ICI therapy) ~5 months BRAF mutated (prior ICI and targeted therapy) ~3 months 1. Chesney J, et
Slide 8: One Third of Responses Remain Ongoing without Subsequent Treatment
One Third of Responses Remain Ongoing without Subsequent Treatment 5-Year OS 19.7% mDOR 36.5 Months ORR 31.4% mOS 13.9 Months 1. Medina et al, ASCO 2025. Pooled Analysis (n=153), Heavily Pre-Treated Patient Population Abbreviations: mDOR, median duration of response; ORR, objective response rate; mO
Slide 9: Best-in-Class Real-World Data Driving Increased Amtagvi Adoption
Best-in-Class Real-World Data Driving Increased Amtagvi Adoption1 1. Karapetyan L et al. Transplantation & Cell Therapy 2026; 2. Three Prior Lines of Therapy (1L-3L): 1L ipilimumab + nivolumab; 2L dabrafenib + trametinib; 3L nivolumab + relatlimab. 86% reduction in target lesions. Response ongoing a
Slide 10: TIL Platform Backbone for Broad Global Solid Tumor Opportunity
TIL Platform Backbone for Broad Global Solid Tumor Opportunity Melanoma Establishes the Infrastructure for All Future Indications Shared Infrastructure Across Expanding Network of 100+ ATCs Forms Base for Scalable Expansion Medical Oncologists Academic & Community Surgeons Tumor Tissue Procurement C
Slide 11: U.S. Manufacturing Facility Dedicated to Global Delivery of TIL Cell Therapies
The only scaled, centralized FDA-approved commercial TIL manufacturing process Consistently improving commercial turnaround (~30 days or less) Faster and more reliable than any TIL therapy in development Modular design 5K+ patient annual capacity Optimal utilization, quality & COS U.S. Manufacturing
Slide 12: >100 ATCs in U.S., Canada & Australia
>100 ATCs in U.S., Canada & Australia1,2 1/3 in Community Setting 10K+ ≤100 Population2 1. Not all authorized treatment centers are listed. 2. U.S. Census Bureau, 2024 Annual Estimates. SEER annual estimated death rate from melanoma: 2 deaths per 100K people: https://seer.cancer.gov/ (accessed Novem
Slide 13: Broad Amtagvi U.S. Market and Geographic Access
Broad Amtagvi U.S. Market and Geographic Access1 1. Data on file as of November 2026. *Plans or policies that cover Amtagvi, including pharmacy benefit managers (PBMs) Abbreviations: ATC, authorized treatment center Lives covered; majority with private coverage* >250M >80% >75% of patients covered b
Slide 14: Tumor Infiltrating Lymphocytes (TIL): Leading Cell Therapy Platform for Solid Tumors
Tumor Infiltrating Lymphocytes (TIL): Leading Cell Therapy Platform for Solid Tumors 1. Amtagvi USPI Circulation Infused TIL circulate in the blood Migration to Tumor Recognition Lysis TIL expansion T cells grown to the billions1 Tumor collection Tumor resected and shipped Individualized therapy One
Slide 15: Deep Pipeline of Registrational Programs
Deep Pipeline of Registrational Programs
Slide 16: Unprecedented Rate, Depth & Durability in Frontline Melanoma
Unprecedented Rate, Depth & Durability in Frontline Melanoma Abbreviations: CR, complete response; DCR, disease control rate; mDOR, median duration of response; ORR, objective response rate; mOS, median overall survival; PD, progressive disease; mPFS, median progression-free survival; PR, partial re
Slide 17: TILVANCE-301 Global Phase 3 and Confirmatory Trial
Option to crossover to lifileucel after BIRC-confirmed PD 1:1 Randomization TILVANCE-301 Global Phase 3 and Confirmatory Trial *Pembrolizumab in both arms is started at the same time after randomization. Abbreviations: APAC, Asia Pacific; BIRC, blinded independent review committee; ORR, objective re
Slide 18: Significant Unmet Need in 2L NSQ NSCLC
>30K Annual Deaths1 1M+ Global Annual Deaths1 Significant Unmet Need in 2L NSQ NSCLC – Limited durability with SOC Chemo (Docetaxel)3 5.6 mo mDOR 12.3 mo OS 12.8% ORR >90K Annual Deaths1 1. Compared to peak revenue potential in U.S. for 2L+ melanoma. Data on file as of November 2026, includes target
Slide 19: IOV-LUN-202 Registrational Trial Design
IOV-LUN-202 Registrational Trial Design Phase 2 Multicenter Study of Lifileucel in Post-Anti-PD-1 NSCLC (NCT04614103) Abbreviations: ALK, anaplastic lymphoma kinase; APAC, Asia Pacific; sBLA, supplemental Biologics License Application; CR, complete response; DCR, disease control rate; DOR, duration
Slide 20: FDA Fast Track Designation in Second-Line Non-squamous mNSCLC
FDA Fast Track Designation in Second-Line Non-squamous mNSCLC Planned sBLA submission to U.S. FDA in 2027 Best Percentage Change From Baseline in Target Lesion by RECIST v1.1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
Slide 21: Unmasking the Biology of TIL in NSCLC
Unmasking the Biology of TIL in NSCLC KRAS Wild-Type Tumors Permissive tumor microenvironment KRAS-Mutant Tumors Suppressive tumor microenvironment Increased IFN-γ IFN-γ TCR–HLA Recognition Lifileucel Non-Squamous NSCLC KRAS Wild-Type More Permissive Cytokine Milieu Active Tumor Killing Reduced IFN-
Slide 22: Best Percentage Change From Baseline in Target Lesion by RECIST v1.1
Best Percentage Change From Baseline in Target Lesion by RECIST v1.1 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Patients [21 / 22 Total] % Change From Baseline Durability of Response1 12 Confirmed Responders + 1 Unconfirmed PR* 19
Slide 23: Frontline Non-Squamous NSCLC subgroup results
Note: Non-squamous, KRASWT + ever-smokers: n=7. ORR = [1 CR + 5 PR]/7 = 85.7%. All responses were confirmed and by RECIST v1.1. NE remains in the denominator. Mean SOD = median lowest recorded percentage change from baseline. ORR includes 15/23 non-squamous patients with numeric change. All TVC leve
Slide 24: Significant Market Opportunity for Advanced Soft Tissue Sarcomas
1. CancerMPact Patient Metrics for U.S. Soft Tissue Sarcoma (accessed November 2026); 2. Zhou et al. BMC Public Health 2025; 3. CancerMPact Treatment Architecture for Sarcoma for the U.S. & EU5 (May 2025) to inform treatment rates in the U.S. and EU5; 4. Parikh RC, et al. Cancer. 2018. 5. Italiano A
Slide 25: Unprecedented Efficacy with Deep, Durable Responses in DDLPS & UPS
Unprecedented Efficacy with Deep, Durable Responses in DDLPS & UPS1 1. Interim data cut as of October 2026 of refractory patients with DDLPS or UPS with minimum cell dose based on FDA feedback in melanoma. 2. Time to response, time on assessment for confirmed responders (PR or better). A bar is pres
Slide 26: SARATOGA (IOV-SAR-201) Registrational Trial
SARATOGA (IOV-SAR-201) Registrational Trial Phase 2 Multicenter Study of Lifileucel in Advanced Soft Tissue Sarcomas (NCT07741877) Abbreviations: CR, complete response; DCR, disease control rate; DDLPS, dedifferentiated liposarcoma; DOR, duration of response; IRC, independent review committee; ORR,
Slide 27: Strong Initial Data for Serous Advanced Endometrial Cancer
National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2026 Estimates. https://seer.cancer.gov (accessed November 2026); 2. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2022; 3. NCCN Guidelines Version 2.2024 Endometrial Carcino
Slide 28: ENDURANCE (IOV-END-201) Phase 2 Trial Endometrial Cancer
pMMR Subgroup* dMMR Subgroup* Endpoints Primary: ORR per RECIST v1.1 by investigator Secondary: CR rate, DOR, DCR, PFS, OS, safety and tolerability ENDURANCE (IOV-END-201) Phase 2 Trial Endometrial Cancer Patient Population Recurrent, metastatic or primary unresectable disease after chemo and anti-P
Slide 29: First-in-class Immuno-Oncology Technologies Target New Indications
First-in-class Immuno-Oncology Technologies Target New Indications
Slide 30: IOV-4001: PD-1 Inactivated TIL Therapy
30 © 2026, Iovance Biotherapeutics, Inc. IOV-4001: PD-1 Inactivated TIL Therapy 2 T cell PD-1 PD-1 inhibits the ability of T cells to fight cancer: T cells, upon encountering cancer cells, produce PD-1, a checkpoint receptor that is activated by proteins (PD-L1 and PD-L2) found on cancer and other i
Slide 31: IOV-4001 Phase 1/2 Study IOV-GM1-201
Phase 1/2 Open-Label First-in-Human Study: IOV-GM1-201 Endpoints Phase 1: Safety (Complete) Phase 2 Primary: ORR per RECIST v1.1 by investigator Secondary: CR rate, DOR, DCR, PFS, OS, safety and tolerability Genetically Modified, PD-1 Inactivated TIL Therapy IOV-4001 in Previously Treated Metastatic
Slide 32: IOV-3001: Next Generation IL-2 for TIL Supportive Regimen
32 © 2026, Iovance Biotherapeutics, Inc. IOV-3001: Next Generation IL-2 for TIL Supportive Regimen1,2 Phase 1/2 trial enrolling patients Recombinant fusion protein designed to enhance TIL survival and cellular proliferation A modified copy of the coding sequence for aldesleukin (mdIL-2) is fused to
Slide 33: IOV-5001: IL-12 Tethered TIL Therapy
IOV-5001: IL-12 Tethered TIL Therapy 1. Zhang L, et al, Clin Cancer Res 2015;21(10):2278–2288; 2. Zhang L, et al, J Immunother Cancer 2020;8:e000210; 3. Kobayashi M, et al, J Exp Med 1989;170:827–845; 4. Zeh HJ, et al, J Immunother 1993;14:155–61; 5. Tugues S, et al, Cell Death and Differentiation 2
Slide 34: POTENTIL (IOV-GE1-201) Phase 1/2 First-in-Human Study
Phase 1/2 First-in-Human Study: POTENTIL (IOV-GE1-201) Endpoints Phase 1: Safety Phase 2 Primary: ORR per RECIST v1.1 by investigator Secondary: CR rate, DOR, DCR, PFS, OS, safety and tolerability Genetically Engineered, IL-12 Tethered TIL Therapy IOV-5001 in Previously Treated Advanced Solid Tumors
Slide 35: Financial Summary
Financial Summary TOVANCE BIOTHERAPEUTICS
Slide 36: Financial Position & Outlook
*The midpoint represents an increase of $55 million, or ~15%, over the previous guidance range of $350 to $370 million. Excludes depreciation and amortization Cash, cash equivalents, short-term investments, and restricted cash as of September 30, 2026 Financial Position & Outlook Full Year 2026 Reve
Slide 37: Thank You
_ TOVANCE BIOTHERAPEUTICS Thank You ADVANCING Lie NO ONC OR GGY 2026, lovance Biotherapeutic:
Iovance Biotherapeutics — Investor Presentation (November 2026) on 6ix